Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could filtered blood transfusions shield cancer Patients' immune systems?

NCT ID NCT00180869

Knowledge-focused Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial asks whether the type of red blood cell transfusion given during cancer surgery affects the body's immune response. It compares standard transfusions with leuko-reduced ones, which have white blood cells removed. The study involves 150 cancer patients undergoing curative surgery with a high chance of needing a transfusion. Researchers will measure immune markers and track infections and survival to see if one approach is gentler on the immune system.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Two types of red blood cell transfusions: unmodified (standard) and leuko-reduced (filtered to remove white blood cells)
What this could lead to
If one transfusion type proves less disruptive to the immune system, it could lead to better recovery and fewer infections after cancer surgery.
What could go wrong
This is a mid-stage trial with 150 participants, so results may not apply to all patients. The immune effects measured are early indicators, not proof of long-term benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

150 people

Start date

Sep 1997

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Surgery for cancer with a transfusion during surgery risk greater than 30% * Surgery in curative intent * Written informed consent Exclusion Criteria: * contraindications to the use of allogeneic unmodified red blood cell concentrate * any anti-RBC and/or anti-HLA and/or anti-granulocyte alloimmunization

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Surgery

Contacts and locations

Locations

  • Institut Gustave Roussy

    Villejuif, 94800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.